{"id":16671,"date":"2025-11-21T12:54:25","date_gmt":"2025-11-21T12:54:25","guid":{"rendered":"https:\/\/www.quantumrun.com\/consulting\/?p=16671"},"modified":"2025-11-24T08:05:43","modified_gmt":"2025-11-24T08:05:43","slug":"why-europe-is-becoming-a-global-hub-for-biologics-manufacturing","status":"publish","type":"post","link":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/","title":{"rendered":"Why Europe is Becoming a Global Hub for Biologics Manufacturing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma ecosystem. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With \u20ac55 billion in annual R&amp;D spending and a unified market of 450 million people, the EU offers unmatched potential for biopharma innovation and production. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Biologics now make up 41% of prescription drug spending in Europe, reflecting their central role in healthcare. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The European Medicines Agency (EMA) sets global regulatory benchmarks, while the continent\u2019s distributed innovation model provides a powerful alternative to the US biopharma hub system.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"512\" height=\"512\" src=\"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\" alt=\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\" class=\"wp-image-16720\" style=\"width:700px\" srcset=\"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp 512w, https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing-300x300.webp 300w, https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing-150x150.webp 150w\" sizes=\"(max-width: 512px) 100vw, 512px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">The Rise of Biologics Manufacturing in Europe<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biologic medicines \u2013 including monoclonal antibodies, biosimilars, and therapeutic proteins \u2013 have transformed Europe\u2019s pharma landscape and significantly increased demand for <strong>biologics manufacturing<\/strong> capacity across the region. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In 2024, <strong>EU countries spent \u20ac95 billion on biologics out of \u20ac228 billion total pharma spending<\/strong>. Europe accounts for nearly 31% of the global biotech market, with major production hubs in Germany, France, Ireland, Italy, Poland, and Switzerland.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The vast majority of European biotech companies are <strong>private SMEs<\/strong>, with only a minority being publicly traded on stock exchanges. For instance, Belgium\u2019s biotech sector has 300+ companies with biotech activities, yet only a handful are listed. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Across Europe as a whole, publicly listed biotech firms likely number in the few hundreds, whereas private biotech companies number in the many thousands.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The life sciences sector adds <strong>\u20ac1.5 trillion in economic value<\/strong> and supports <strong>29 million jobs<\/strong> across Europe. Moreover, Europe\u2019s biotech sector is growing faster than many other regions, thanks to strong private and public investment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Key Factors Driving Europe\u2019s Leadership in Biologics Production<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Europe boasts a rich heritage in the life sciences, with world-class universities, research institutes, and a history of groundbreaking discoveries. The European regulatory environment for biologics is considered the gold standard worldwide. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Through a centralized approval process, the <strong>European Medicines Agency (EMA)<\/strong> ensures that biologics meet stringent criteria for safety, quality, and efficacy across all EU markets. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Notably, <strong>Europe pioneered the regulation of biosimilars<\/strong>, establishing a regulatory framework in 2004 and approving the world&#8217;s first biosimilar in 2006.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EU\u2019s single market allows seamless scaling of biologics across member states, with robust cross-border collaboration between academic and industrial players. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike the U.S., where innovation is regionally clustered, Europe hosts a distributed network of biotech hubs\u2014from Oxford and Medicon Valley to Central and Eastern Europe.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Investment, Innovation, and Infrastructure Behind Europe\u2019s Growth<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In 2025, the European Commission launched a <strong>Biotech and Biomanufacturing Hub<\/strong> to support SMEs and startups with funding and regulatory access. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Horizon Europe is allocating <strong>\u20ac100M for microbiome solutions<\/strong>, <strong>\u20ac250M for advanced life sciences technologies<\/strong>, and <strong>\u20ac300M for public procurement of next-gen biologics<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EU also proposes an \u201c<strong>EU Biotech Act<\/strong>\u201d to streamline regulatory approval, promote cross-border cooperation, and encourage public-private partnerships. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This could involve streamlined approval processes, adaptive regulatory pathways for novel therapies, and better alignment of rules across member states. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By reducing red tape and uncertainty, Europe hopes to encourage companies (especially startups) to develop new biologics in the EU.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">End-to-End Biologics Manufacturing Expertise &#8211; Europe\u2019s Competitive Edge<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In Europe, all major CDMOs operating in the biopharmaceutical sector have a significant presence. As of 2025, Europe\u2019s pharmaceutical outsourcing sector is supported by about <strong>337 CDMO companies<\/strong>, which collectively operate over <strong>550 manufacturing facilities<\/strong> on the continent. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These CDMOs provide services ranging from drug substance production to finished dosage manufacturing for biotech and pharma clients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Europe\u2019s integrated CDMO ecosystem<\/strong> offers complete services from cell line development to distribution, forming one of the most advanced <strong>biologics manufacturing<\/strong> support infrastructures worldwide. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The region is self-reliant for 77% of biologic ingredients, enhancing supply chain security. Logistics infrastructure and single-market access support timely delivery across the continent.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mabion<\/strong>, a Poland-based CDMO, exemplifies this model. Offering upstream and downstream processing, fill-finish, and in-house logistics, <strong>Mabion delivers end-to-end solutions with regulatory support across Europe<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Its ability to transport clinical and commercial products across EU borders highlights the operational efficiency of European biologics CDMOs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Future Outlook for Biosimilars in Global Healthcare<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a style=\"text-decoration: none;\" href=\"https:\/\/www.mabion.eu\/science-hub\/articles\/end-to-end-manufacturing-of-biosimilars\/\" class=\"external\">Biosimilars<\/a> represent one of the most significant contributions of Europe to global healthcare, and their future outlook is closely tied to Europe\u2019s ongoing leadership. Europe pioneered biosimilar regulation and remains a <strong>global leader<\/strong>, accounting for <strong>40% of global biosimilar value in 2025<\/strong>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These drugs have saved <strong>\u20ac56 billion<\/strong> across EU health systems from 2013 to 2024. As 100+ biologics lose exclusivity by 2030, biosimilar uptake will continue to rise. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With EMA\u2019s streamlined approval and growing market trust, Europe is positioned to lead the next wave of biosimilar innovation, shaping global access to biologic therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma ecosystem. With \u20ac55 billion in annual R&amp;D spending and a unified market of 450 million people, the EU offers unmatched potential for biopharma innovation and production. Biologics now make up 41% of prescription drug [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":16720,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[218],"tags":[],"class_list":["post-16671","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Why Europe is Becoming a Global Hub for Biologics Manufacturing<\/title>\n<meta name=\"description\" content=\"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\" \/>\n<meta property=\"og:description\" content=\"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/\" \/>\n<meta property=\"og:site_name\" content=\"Quantumrun Foresight\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-21T12:54:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T08:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Richard Jaimes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Richard Jaimes\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/\"},\"author\":{\"name\":\"Richard Jaimes\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\"},\"headline\":\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\",\"datePublished\":\"2025-11-21T12:54:25+00:00\",\"dateModified\":\"2025-11-24T08:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/\"},\"wordCount\":756,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/\",\"name\":\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\",\"datePublished\":\"2025-11-21T12:54:25+00:00\",\"dateModified\":\"2025-11-24T08:05:43+00:00\",\"description\":\"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp\",\"width\":512,\"height\":512,\"caption\":\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blog\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Why Europe is Becoming a Global Hub for Biologics Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"name\":\"Quantumrun Foresight\",\"description\":\"Thrive from future trends.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\",\"name\":\"Quantumrun Foresight\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"width\":286,\"height\":55,\"caption\":\"Quantumrun Foresight\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\",\"name\":\"Richard Jaimes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"caption\":\"Richard Jaimes\"},\"sameAs\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\"],\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/author\\\/admin-stcons\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why Europe is Becoming a Global Hub for Biologics Manufacturing","description":"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/","og_locale":"en_US","og_type":"article","og_title":"Why Europe is Becoming a Global Hub for Biologics Manufacturing","og_description":"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma","og_url":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/","og_site_name":"Quantumrun Foresight","article_published_time":"2025-11-21T12:54:25+00:00","article_modified_time":"2025-11-24T08:05:43+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp","type":"image\/webp"}],"author":"Richard Jaimes","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Richard Jaimes","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#article","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/"},"author":{"name":"Richard Jaimes","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011"},"headline":"Why Europe is Becoming a Global Hub for Biologics Manufacturing","datePublished":"2025-11-21T12:54:25+00:00","dateModified":"2025-11-24T08:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/"},"wordCount":756,"commentCount":0,"publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/","url":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/","name":"Why Europe is Becoming a Global Hub for Biologics Manufacturing","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#primaryimage"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp","datePublished":"2025-11-21T12:54:25+00:00","dateModified":"2025-11-24T08:05:43+00:00","description":"Europe is rapidly emerging as a global leader in biologics manufacturing, driven by strategic investments, regulatory excellence, and a robust biopharma","breadcrumb":{"@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#primaryimage","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2025\/11\/Why-Europe-is-Becoming-a-Global-Hub-for-Biologics-Manufacturing.webp","width":512,"height":512,"caption":"Why Europe is Becoming a Global Hub for Biologics Manufacturing"},{"@type":"BreadcrumbList","@id":"https:\/\/www.quantumrun.com\/consulting\/why-europe-is-becoming-a-global-hub-for-biologics-manufacturing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.quantumrun.com\/consulting\/"},{"@type":"ListItem","position":2,"name":"Blog","item":"https:\/\/www.quantumrun.com\/consulting\/blog\/"},{"@type":"ListItem","position":3,"name":"Why Europe is Becoming a Global Hub for Biologics Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/www.quantumrun.com\/consulting\/#website","url":"https:\/\/www.quantumrun.com\/consulting\/","name":"Quantumrun Foresight","description":"Thrive from future trends.","publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.quantumrun.com\/consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.quantumrun.com\/consulting\/#organization","name":"Quantumrun Foresight","url":"https:\/\/www.quantumrun.com\/consulting\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","width":286,"height":55,"caption":"Quantumrun Foresight"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011","name":"Richard Jaimes","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","caption":"Richard Jaimes"},"sameAs":["https:\/\/www.quantumrun.com\/consulting"],"url":"https:\/\/www.quantumrun.com\/consulting\/author\/admin-stcons\/"}]}},"_links":{"self":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/16671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/comments?post=16671"}],"version-history":[{"count":2,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/16671\/revisions"}],"predecessor-version":[{"id":16722,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/16671\/revisions\/16722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media\/16720"}],"wp:attachment":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media?parent=16671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/categories?post=16671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/tags?post=16671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}